Literature DB >> 29392021

The Role and Importance of Molecular Tests in Approach to Thyroid Nodules.

Levent Gürbüzler1.   

Abstract

Although there is a significant increase in the detection of thyroid cancer because of the widespread utilization of ultrasound and fine needle aspiration biopsy, sometimes these techniques prove inefficient for diagnosis. Therefore, improved diagnostic tools are required. Increasing knowledge regarding thyroid cancer genetics has revived molecular testing. The possibility of thyroid malignancy can be considered or ruled out because of the high accuracy of results, such as 90% positive predictive value (PPV) and 96% negative predictive value (NPV), obtained from the molecular tests. Although the molecular biology of all thyroid cancers has not been completely understood, the remarkable progress done in this domain has widened the horizon of their diagnosis, prognosis and treatment.

Entities:  

Keywords:  BRAF; RAS; RET/PTC; Thyroid cancer; molecular test; thyroid nodule

Year:  2016        PMID: 29392021      PMCID: PMC5782937          DOI: 10.5152/tao.2015.1276

Source DB:  PubMed          Journal:  Turk Arch Otorhinolaryngol        ISSN: 2667-7466


  27 in total

1.  Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer.

Authors:  David S Cooper; Gerard M Doherty; Bryan R Haugen; Bryan R Hauger; Richard T Kloos; Stephanie L Lee; Susan J Mandel; Ernest L Mazzaferri; Bryan McIver; Furio Pacini; Martin Schlumberger; Steven I Sherman; David L Steward; R Michael Tuttle
Journal:  Thyroid       Date:  2009-11       Impact factor: 6.568

2.  Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial.

Authors:  Marcia S Brose; Christopher M Nutting; Barbara Jarzab; Rossella Elisei; Salvatore Siena; Lars Bastholt; Christelle de la Fouchardiere; Furio Pacini; Ralf Paschke; Young Kee Shong; Steven I Sherman; Johannes W A Smit; John Chung; Christian Kappeler; Carol Peña; István Molnár; Martin J Schlumberger
Journal:  Lancet       Date:  2014-04-24       Impact factor: 79.321

Review 3.  An update on molecular biology of thyroid cancers.

Authors:  Ozgur Omur; Yusuf Baran
Journal:  Crit Rev Oncol Hematol       Date:  2013-12-18       Impact factor: 6.312

4.  Preoperative diagnosis of benign thyroid nodules with indeterminate cytology.

Authors:  Erik K Alexander; Giulia C Kennedy; Zubair W Baloch; Edmund S Cibas; Darya Chudova; James Diggans; Lyssa Friedman; Richard T Kloos; Virginia A LiVolsi; Susan J Mandel; Stephen S Raab; Juan Rosai; David L Steward; P Sean Walsh; Jonathan I Wilde; Martha A Zeiger; Richard B Lanman; Bryan R Haugen
Journal:  N Engl J Med       Date:  2012-06-25       Impact factor: 91.245

5.  Role of BRAF molecular analysis in the management of papillary thyroid carcinoma: analysis of cytological and histological samples.

Authors:  L Capelli; C Marfisi; M Puccetti; L Saragoni; F De Paola; A Zaccaroni; E Chiadini; L Gagliardi; G Ferretti; W Zoli; P Ulivi
Journal:  Cytopathology       Date:  2014-08-14       Impact factor: 2.073

Review 6.  Clinical application of molecular testing of fine-needle aspiration specimens in thyroid nodules.

Authors:  Linwah Yip; Robert L Ferris
Journal:  Otolaryngol Clin North Am       Date:  2014-06-12       Impact factor: 3.346

7.  Cost-effectiveness analysis of repeat fine-needle aspiration for thyroid biopsies read as atypia of undetermined significance.

Authors:  Michael Heller; Kyle Zanocco; Sara Zydowicz; Dina Elaraj; Ritu Nayar; Cord Sturgeon
Journal:  Surgery       Date:  2012-09       Impact factor: 3.982

8.  Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation.

Authors:  Laurie L Carr; David A Mankoff; Bernardo H Goulart; Keith D Eaton; Peter T Capell; Elizabeth M Kell; Julie E Bauman; Renato G Martins
Journal:  Clin Cancer Res       Date:  2010-09-16       Impact factor: 12.531

9.  Prevalence of Ras mutations in thyroid neoplasia.

Authors:  C T Esapa; S J Johnson; P Kendall-Taylor; T W Lennard; P E Harris
Journal:  Clin Endocrinol (Oxf)       Date:  1999-04       Impact factor: 3.478

10.  RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma.

Authors:  Marina N Nikiforova; Roy A Lynch; Paul W Biddinger; Erik K Alexander; Gerald W Dorn; Giovanni Tallini; Todd G Kroll; Yuri E Nikiforov
Journal:  J Clin Endocrinol Metab       Date:  2003-05       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.